Dr. Jennifer Nelson explains how Kaiser Permanente scientists are helping the CDC and FDA keep an eye out for rare adverse events.
Dr. Diana Buist reflects on the challenges of providing screening during a pandemic — and finds reason for optimism.
The investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of about 94% as research continues.
KPWHRI responded to the COVID-19 hurricane with actions to improve health worldwide.
In a Viewpoint for JAMA, KPWHRI’s Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
KPWHRI psychologist and researcher Ben Balderson, PhD, shares advice for keeping our spirits up during this most unusual holiday season.
The investigational mRNA vaccine is also well tolerated, according to trial led by Kaiser Permanente Washington researcher and others.